Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

SANTA BARBARA, Calif. and PARSIPPANY, N.J., February 27, 2025 /3BL/ - Direct Relief, Teva Pharmaceuticals, and the National ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...

In particular, the third quarter of the fiscal year also saw record revenue and margins, with the gross margin improving by 1.6 percentage points from 58.7% to 60.3%. The company's UGG and Hoka brands ...

Catalyst Pharmaceuticals Inc (CPRX) reports a robust 28.3% revenue increase in Q4 2024, driven by strong product performance ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

Headquartered in Goleta, California, Deckers Outdoor Corporation (DECK) is a leading designer, marketer, and distributor of ...

1 Day TEVA 1.97% DJIA 0.02% S&P 500 0.24% Health Care/Life Sciences 0.00% ...